Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Revision History For: CTIC =MC $97 M / Covid 19 Drug Phase 3 Data in Q4 =MEGA OPP

No earlier versions found for this Subject.

Return to CTIC =MC $97 M / Covid 19 Drug Phase 3 Data in Q4 =MEGA OPP

(CTIC-DD) Market Cap $97 Million / Cash $81 Million or enough untill Q1 2022 / 2 Phase 3 Gems including Covid 19 Drug with Phase 3 results coming later this year / Strong Institutional ownership = Could run to $10++ and more very attractive Invesmtent here .STRONG BUY and GL

Cti Biopharma (CTIC)

Market Cap:$97 Million

Cash: $81 Million

Price: $1.34

Shares Out: 73.7 Million

Presentation
cbc.gcs-web.com

CTI BioPharma Announces Enrollment of First Patient in COVID-19 PRE-VENT Phase 3 Clinical Trial
finance.yahoo.com

- Company Expects to Report Topline Data by the End of 2020 -

Largest Shareholder :

OrbiMed ...9.5M
New Enterprise ...7.1M
BVF Partners L.P...6.9M
Stonepine ...6.4M
Medical Strategy ...2.3M
The Vanguard ...2.1M
Renaissance ...2.1M
BlackRock ...753.3K
Caxton Associates LP...616.7K

Geode Capital ...416.0K